StockNews.com initiated coverage on shares of Alimera Sciences (NASDAQ:ALIM – Get Rating) in a research report issued to clients and investors on Thursday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.
ALIM has been the subject of several other reports. HC Wainwright decreased their price objective on shares of Alimera Sciences from $12.00 to $10.00 and set a “buy” rating for the company in a report on Friday, February 25th. Zacks Investment Research raised shares of Alimera Sciences from a “strong sell” rating to a “hold” rating in a report on Wednesday, April 27th. Finally, Alliance Global Partners lowered their price objective on shares of Alimera Sciences from $14.50 to $11.00 in a research note on Friday, February 25th.
Shares of NASDAQ:ALIM opened at $5.45 on Thursday. The company has a 50 day moving average of $5.52 and a 200 day moving average of $5.09. The stock has a market cap of $38.11 million, a P/E ratio of -6.90 and a beta of 1.48. Alimera Sciences has a 12 month low of $3.94 and a 12 month high of $10.50.
In other Alimera Sciences news, major shareholder Stanley Morgan sold 250,000 shares of the business’s stock in a transaction dated Tuesday, February 8th. The shares were sold at an average price of $4.55, for a total value of $1,137,500.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 13.50% of the company’s stock.
Hedge funds have recently modified their holdings of the company. Ensign Peak Advisors Inc purchased a new stake in Alimera Sciences in the third quarter valued at approximately $81,000. Millennium Management LLC acquired a new position in shares of Alimera Sciences during the 4th quarter worth approximately $65,000. Finally, Morgan Stanley raised its stake in shares of Alimera Sciences by 0.7% during the 2nd quarter. Morgan Stanley now owns 428,109 shares of the biopharmaceutical company’s stock worth $3,896,000 after buying an additional 2,797 shares during the period. Institutional investors and hedge funds own 40.97% of the company’s stock.
About Alimera Sciences (Get Rating)
Alimera Sciences, Inc, a pharmaceutical company, engages in the development and commercialization of ophthalmic pharmaceuticals in the United States and internationally. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye.
- Get a free copy of the StockNews.com research report on Alimera Sciences (ALIM)
- Limelight Networks Stock is a Speculative Turnaround Opportunity
- The Selloff In SiteOne Landscape Supply Is Overextended
- Camping World Confirms Support At Institutional Bottom
- What’s Next For Starbucks (NASDAQ: SBUX)?
- 3 Earnings Plays With Big Move Potential
Receive News & Ratings for Alimera Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences and related companies with MarketBeat.com's FREE daily email newsletter.